Clinical research has shown that L-Carnitine supports athletic performance and endurance
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
However, when prescribed for weight loss, insurance coverage tends to be less consistent, as weight loss medications like Wegovy are not universally covered
Dosing Notes Inject on an empty stomach
Nevertheless, the belief that carnitine is a slimming agent has been negated in the middle of 90s [20]
Reduce to once-daily evening application only